Temocillin Pharmacokinetic in Hemodialysis

• Status: Completed
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The current study aimed to explore the pharmacokinetics of temocillin in patients treated with haemodialysis and to demonstrated whether or not the pharmacodynamics target of a time above a MIC of 16 mg/L of more than 40 and 60 % of the dosing interval could be obtained with a dosing schedule of 1 gram/24 hours, 2 gram/48 hours and 3 gram/72 hours, all of these doses given after haemodialysis sessions only.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AZ Sint-Jan AV
• Collaborators: Ana Miranda Bastos, Louvain drug research institute, belgium; Francoise Van Bambeke, Louvain drug research institute, belgium; Paul Tulkens, Louvain drug research institute, belgium
• Treatments: Penicillins; Temocillin

Criteria

Inclusion Criteria:

• all patients under treatment with haemodialysis for ESRD for whom a treatment with temocillin was indicated according to the attending physician were eligible for the study.

Exclusion Criteria:

• an age of less than 18 years

• an estimated life-expectance of < 24 hours due to major co-morbid conditions

• pregnancy

• an IgE-mediated allergy to penicillins

• patients not giving informed consent.